A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer
A phase 2 trial of Iruplinalkib in Non-small-cell lung cancer, run by Qilu Pharmaceutical Co., Ltd., with a status the registry has not verified recently.
Overview
A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT04641754 by Qilu Pharmaceutical Co., Ltd., with 176 participants planned, started 2019-03-07 and due to reach its primary completion in 2020-12. Interventions recorded: WX-0593 Tablets. Conditions recorded: Non-small Cell Lung Cancer.
Linked to the drug Iruplinalkib because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialStudy Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Shares Iruplinalkib, Qilu Pharmaceutical, Non-small-cell lung cancer and the tag pipeline.
- TrialNeoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer
Shares Iruplinalkib, Non-small-cell lung cancer and the tag pipeline.
- TrialGM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer
Shares Qilu Pharmaceutical and the tag pipeline.
- TrialPhase II Study of QLC2519 in Pediatric Solid Tumor Participants
Shares Qilu Pharmaceutical and the tag pipeline.
- TrialStudy of MHB088C for Patients With Advanced Solid Malignant Tumors
Shares Qilu Pharmaceutical and the tag pipeline.
- TrialPhase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients
Shares Qilu Pharmaceutical and the tag pipeline.
- Triala Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy
Shares Qilu Pharmaceutical and the tag pipeline.
- TrialA Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients
Shares Qilu Pharmaceutical and the tag pipeline.